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Abstract 
 
BACKGROUND: Arterial hypertension is associated with autonomic nervous system 
dysfunction. Different interventional strategies have been implemented in recent years for the 
reduction of sympathetic activity in subjects with hypertension. However, the therapeutic 
benefit of increasing vagal tone in hypertensive subjects remains largely unexplored.  
OBJECTIVE: Here we describe the effects of long-term activation of vagal neural pathways 
on arterial pressure (AP), heart rate (HR), AP variability and spontaneous baroreflex 
sensitivity in spontaneously hypertensive rats (SHR) and normotensive Wistar rats.  
METHODS: Brainstem vagal preganglionic neurons residing in the dorsal vagal motor 
nucleus (DVMN) were targeted with a lentiviral vector to induce the expression of an 
artificial G(s) protein-coupled receptor termed Designer Receptors Exclusively Activated by 
Designer Drugs (DREADD-Gs). The transduced neurons were activated daily by systemic 
administration of otherwise inert ligand clozapine-n-oxide (CNO). AP measurements were 
recorded in conscious freely-moving animals after 21 consecutive days of DVMN 
stimulation.  
RESULTS: Resting AP was significantly lower in SHRs expressing DREADD-Gs in the 
DVMN, compared to control SHRs expressing eGFP. No changes in AP were detected in 
Wistar rats expressing DREADD-Gs compared to rats expressing eGFP in the DVMN. 
Pharmacogenetic activation of DREADD-Gs-expressing DVMN neurons in SHRs was 
accompanied with increased baroreflex sensitivity and a paradoxical decrease in cardio-vagal 
components of HR and systolic AP variability in SHRs. 
CONCLUSION: These results suggest that long-term activation of vagal parasympathetic 
pathways is beneficial in restoring autonomic balance in an animal model of neurogenic 
hypertension and might be an effective therapeutic approach for the management of 
hypertension.  
 
 
 
 
 
 
Introduction 
 Arterial hypertension increases the risk of death from cardiovascular disease in adults 
aged between 40-69 years (1). Arterial hypertension is believed to affect one in four people 
and accounts for approximately one billion cases worldwide (2). Increased arterial blood 
pressure is one of the most crucial cardiovascular risk factors and has a dominant role in the 
pathogenesis of ischemic heart disease, heart failure, stroke, kidney failure and overall 
cardiovascular death. Despite important advances in the diagnosis and treatment of arterial 
hypertension, a significant proportion of patients have insufficient disease management due 
to either resistance to current drug therapy (3) or poor drug compliance. Thus, there is a 
significant unmet clinical need to find alternative strategies to conventional pharmacotherapy. 
 Over the last three decades, a growing body of evidence has unequivocally shown that 
both the development and maintenance of arterial hypertension are intimately linked to 
autonomic dysfunction, characterized by increased sympathetic activity (4; 5) and reduced 
cardio-vagal tone (6). The great majority of pre-clinical and clinical studies have historically 
concentrated on the detrimental effects of sustained sympathetic nervous system (SNS) 
overactivity on arterial blood pressure control (7-12). This has generated considerable interest 
in novel autonomic modulation approaches such as renal nerve ablation (13), deep brain 
stimulation (14) and carotid sinus stimulation (15) which have been shown to lower SNS 
activity, reduce arterial blood pressure levels and prevent end-organ damage, particularly in 
treatment-resistant subjects. However, the pathophysiological role of impaired vagal function 
in arterial hypertension remains largely unexplored and despite considerable evidence 
showing the beneficial effects of vagal nerve modulation on cardiovascular function (16), it 
remains unknown whether direct activation of vagal efferent pathways could attenuate the 
progression of the disease. Here, we employed a pharmacogenetic approach in the 
spontaneously hypertensive rat model to investigate the physiological consequences of long-
term activation of vagal preganglionic neurons on the development of arterial hypertension. 
 
Methods 
Animals 
 All animal experimentations were carried out in accordance with guidelines approved 
by University of São Paulo Institutional Animal Care and Use Committee (CEUA: 118/109-
2). Experiments were performed on male adult hypertensive SHRs (8 weeks of age) and age-
matched normotensive Wistar rats. 
 
Viral vectors  
 Vagal preganglionic neurons of the DVMN, which express the transcriptional factor 
Phox2, were transduced using an artificial Phox2-activated promoter-PRSx8 as described 
previously (17-20). The DVMN neurons were targeted with a lentiviral vector to express an 
artificial G protein-coupled receptor (GPCR) termed Designer Receptors Exclusively 
Activated by Designer Drugs (DREADD). These are mutated muscarinic receptors, which are 
selectively activated by an otherwise biologically inert ligand clozapine-N-oxide (CNO) (21). 
A Gs-coupled version of this system (DREADD-Gs) fused with enhanced green fluorescent 
protein (eGFP) was used to activate neurons in a similar manner to that following activation 
of other Gs-coupled receptors. A lentiviral construct was used to induce the expression of 
DREADD-Gs in DVMN neurons under the control of the PRSX8 promoter (PRSx8-
DREADD-Gs-eGFP-LV). For control experiments, DVMN neurons were transduced with a 
lentiviral vector to express eGFP (PRSx8-eGFP-LV). Vectors were generated in our 
laboratory facilities as described previously using a DREADDs construct kindly provided by 
J. Wess (22, 23). LVV titers were approximately between 1×1012 transducing units ml−1. 
Validation of efficacy of CNO-induced activation of Gs signaling in cells expressing 
DREADD-Gs was described in detail previously (22). 
In vivo gene transfer  
 Rats were anesthetized [ketamine (80 mg kg-1; ip) and xylasine (7 mg kg−1, ip)] and 
placed in a stereotaxic frame (model 900; David Kopf Instruments). Adequate level of 
anesthesia was confirmed by the absence of a withdrawal response to a paw pinch. SHRs and 
Wistar rats were injected in the DVMN with two microinjections per side (0.25 μL each, 0.05 
μL min-1) of a viral suspension containing PRSx8-DREADD-Gs-eGFP-LV (DREADD-Gs; 
n=8 and n=4, respectively) or PRSx8-eGFP-LV (e-GFP, n=7 and n=5, respectively) using the 
following coordinates from calamus scriptorius (i) 0.5 mm rostral, 0.6 mm lateral, 0.8 mm 
ventral and (ii) 1.0 mm rostral, 0.8 mm lateral, 0.6 mm ventral. Anesthesia was reversed with 
atipamezole (1 mg kg-1). All animals recovered normally without complications, received 
daily injections of buprenorphine for post-operative analgesic control (0.05 mg kg-1 
subcutaneously for 5 days) and gained weight as expected for their age and size. 
 
Application of CNO 
 Systemic administration of CNO allowed us to activate Gs signaling in DVMN 
neurons expressing DREADDs-Gs. The dose of CNO (0.3 mg/kg in 0.1 ml, subcutaneously) 
was based on the lowest concentration used in a previous study that was found to elicit robust 
activation of targeted neuronal populations and behavioral changes in conscious animals (24, 
25). Animals were allowed to recover from viral gene transfer surgery for 8 days before the 
start of CNO treatment. CNO injections were delivered daily by the same experimenter and at 
the same time every day for 21 consecutive days.  
 
Arterial blood pressure measurements  
 After 19 days of CNO treatment (i.e., at 11 weeks of age), rats were implanted with 
intra-arterial catheters. Animals were anesthetized with halothane (3% in O2) and a 
polyethylene tube (PE-10 connected to PE-50; Clay Adams, Parsippany, NJ, USA) filled with 
sterile saline containing heparin (50 U ml-1) and penicillin G (2000 U ml-1) was inserted into 
the left femoral artery and its tip was placed in the abdominal aorta caudal to the renal 
arteries (26). The opposite end was tunneled subcutaneously and exteriorized through the 
upper back and sealed with a plastic cap. All animals received an intramuscular injection of 
penicillin G (24,000 IU) and streptomycin (10 mg). Catheters were flushed the following day 
with the same solution containing heparin and penicillin. Arterial pressure recordings were 
performed 2 days after arterial catheterization. On the day of the experiments, the catheter 
was connected to a pressure transducer (MLT844, ADInstruments, Sydney, NSW, Australia) 
coupled to a preamplifier (Bridge Amp, ML221, ADInstruments, Sydney, NSW, Australia) 
that was connected to a Powerlab computer data acquisition system (PowerLab 16/30, 
ML880, ADInstruments). Arterial pressure measurements were taken between 8 am and 5 pm 
by an experimenter that was blind to the animal condition. Data was acquired in conscious 
animals for 60 minutes during quiet resting periods.  
 
Power spectral analysis 
 Spectral analysis of the systolic pressure variability was performed off-line to 
estimate the relative level of sympathetic and parasympathetic activity in rats at 11 weeks of 
age. Mean, systolic and diastolic arterial pressures (MAP, SAP, and DAP; mmHg, 
respectively), pulse interval (PI; ms) and heart rate (HR; bpm) were measured from the AP 
recording using LabChart 8.0 (model Powerlab 8SP ADInstruments). Data was acquired after 
a 10 minute period of stabilization. Only data sets containing stable measurements of SAP 
and PI without artifacts or large sudden blood pressure changes were selected for analysis. 
An algorithm was used to detect beat-to-beat inflection points in the PAP signal. SAP and PI 
variability analysis was carried out in time and frequency domains using custom software 
CardioSeries V2.4 (http://www.danielpenteado.com/) as described previously (27). Briefly, 
SAP and PI power spectral density were estimated by Fast Fourier Transform algorithm for 
time series. Using 10 Hz of interpolation rate, beat-by-beat series were divided in half 
overlapping sequential sets with 512 points. The spectra of SAP and PI were integrated into a 
low-frequency band (LF: 0.2-0.75 Hz, indicating mainly sympathetic influences) and a high-
frequency band (HF: 0.75-3 Hz, indicative mainly of cardio-vagal tone). The results were 
expressed in absolute (ms2) and normalized units (nu) obtained by calculating the percentage 
of LF and HF power with regard to the total power of the spectrum minus the very low 
frequency band (VLF: <0.2 Hz) (28). Sympathovagal balance was also calculated by 
assessing the LF/HF ratio of PI variability (27-30). 
 
Spontaneous baroreflex sensitivity (BRS) 
 A beat-by-beat time series of SAP and PI was scanned in a 60-min data set acquired 
during quiet rest, searching for sequences of at least four consecutive beats in which AP 
increases were followed by PI lengthening (up-sequence) and AP decreases were followed by 
PI shortening (down-sequence) with a delay of 0, with no threshold in SAP and PIs and a 
linear correlation of >0.8. The slope of the linear regression lines between systolic SAP and 
PI was taken as a measure of spontaneous BRS. The baroreflex effectiveness index, which 
provides information on baroreflex function that is complementary to spontaneous BRS, was 
also calculated (31). It was defined as the ratio between the number of SAP ramps followed 
by respective reflex changes in PI and the total number of SAP ramps (independent of 
whether accompanied by the corresponding reflex PI ramps) observed over the time window 
studied. 
Immunohistochemistry procedures 
 At the end of the in vivo experiments, the rats transduced to express DREADD-Gs or 
eGFP in the DVMN neurons were deeply anesthetized with sodium pentobarbital (60 mg/kg), 
injected with heparin (500 units, intracardially) and perfused through the ascending aorta 
with 0.9% saline solution followed by 4% phosphate-buffered (0.1 M, pH 7.4) 
paraformaldehyde. After 12 h of post-fixation and subsequent cryoprotection in 30% sucrose, 
40-μm-thick coronal sections were collected along the rostro-caudal extent of the medulla 
oblongata. Sections were processed for the immunohistochemical detection of choline acetyl-
transferase (ChAT). Tissue was incubated in goat anti-ChAT (1:500, Chemicon, raised 
against human placental ChAT) followed by donkey anti-goat Alexa Fluor 594 (Jackson). 
The speciﬁcity of the antibodies has been validated previously (32; 33). 
 
Cell mapping, counting and imaging 
 A conventional multifunction microscope [brightfield, darkfield and epifluorescence; 
Zeiss Axioskop 2 microscope (Oberkochen, Germany)] was used for all observations except 
when indicated. ImageJ software (NIH) was used to count the various types of neuronal 
profiles within a defined area. 
 A one-in-six series of 40-µm brain sections was used per rat, for a total distance of 
240 µm of separation between slices. The sections were counted bilaterally, and the numbers 
reported correspond exactly to the counts obtained in one series of sections. Section 
alignment between brains was completed relative to a reference section. Briefly, to align 
sections around the nucleus of the solitary tract (NTS) level, the section containing the mid-
area postrema was identified in each brain and assigned the level 13.8 mm caudal to Bregma 
(Bregma = -13.8 mm). Levels rostral or caudal to this reference section were determined by 
adding a distance corresponding to the interval between sections multiplied by the number of 
intervening sections.  
Photographs were taken with a 12-bit color CCD camera (CoolSnap, Roper Scientific, 
Tuscon, AZ; resolution 1392 X 1042 pixels). The files were exported to the Canvas 9 
software-drawing program for final modifications. The neuroanatomical nomenclature is 
based on Paxinos and Watson Atlas of Neuroanatomy (34). 
 
Data analysis 
Data normality was assessed using the Shapiro-Wilk test, and all the normally-
distributed data were expressed as the mean ± SEM. The data regarding number of neurons 
(ChAT+, ChAT+/eGFP+) and cardiovascular variables (i.e SAP, DAP, MAP, HR) were 
compared between groups and across time points using two-way ANOVA, with repeated 
measures for only the time factor. When applicable, the Student Newman Keuls post hoc test 
was used. Sigma Stat version 3.0 package (Jandel Corporation, Point Richmond, CA, USA) 
was used for all analysis. Significance level used was p<0.05. 
 
Results 
1) Expression of DREADD-Gs-eGFP in DVMN neurons.  
The number and location of neurons expressing DREADD-Gs in the DVMN was 
mapped in each rat by identifying DREADD-Gs-eGFP fluorescence signal in vagal 
preganglionic neurons immunoreactive to ChAT (Figs. 1A-C). On average, DREADD-Gs 
was detected in 220±13 neurons counted in 5 coronal sections (n=7). Of the neurons 
expressing DREADD-Gs in all counted sections, 94±5% had detectable ChAT-
immunoreactivity. Thus, 70±6% of ChAT-immunoreactive neurons in the DVMN were 
found to express the transgene (Fig. 1D).  
2) Effect of long-term activation of DVMN neurons on arterial blood pressure 
 Figure 2 shows arterial blood pressure measurements obtained in SHRs and Wistar 
rats expressing DREADD-Gs or control eGFP after administration of CNO for 21 
consecutive days. Arterial blood pressure levels were significantly lower in SHRs transduced 
to express DREADD-Gs in the DVMN compared to SHRs expressing eGFP (Figs. 2A-B). 
The SAP was 159.8±2 in SHRs expressing DREADD-Gs, vs. 177.6±3 mmHg in SHRs 
expressing eGFP [F(3,31) = 183,89; p<0.001]; DAP was 114.3±1.8 in SHRs expressing 
DREADD-Gs, vs. 124±2.7 mmHg in SHRs expressing eGFP [F(3,31) = 40,55; p<0.01]; MAP 
was 129.5±1.5 in SHRs expressing DREADD-Gs, vs. 142±1.2 mmHg in SHRs expressing 
eGFP [F(3,31) = 165,73; p<0.001] (Figs. 2A-C). HR was also found to be lower in SHRs 
expressing DREADD-Gs in the DVMN (302±5 bpm) compared to SHRs expressing eGFP 
(370±6 bpm, [F(3,31) = 68,08; p<0.01]; Fig. 2D). Resting SAP, DAP, MAP and HR were 
significantly higher in SHRs expressing DREADD-Gs compared to Wistar rats expressing 
either DREADD-Gs or eGFP (p = 0.021) (Figs. 2A-D). Cardiovascular parameters were not 
different between control Wistar rats expressing DREADD-Gs or eGFP in the DVMN (Figs. 
2A-D). 
 
3. Repetitive activation of DVMN neurons increases spontaneous baroreflex sensitivity 
 Figures 3A and B show the spontaneous baroreflex sensitivity gain and baroreflex 
effectiveness index in SHRs and Wistar rats transduced to express DREADD-Gs or eGFP in 
the DVMN. The results showed that rats from both groups expressing DREADD-Gs in the 
DVMN had higher spontaneous baroreflex sensitivity (7.7±0.7 in SHRs expressing 
DREADD-Gs, vs. 4.7±0.6 in SHRs expressing eGFP, p = 0.024 and 7.3±0.5 in Wistars 
expressing DREADD-Gs vs. 5.1±0.7 in Wistars expressing eGFP, p = 0.03) and baroreflex 
effectiveness index (0.15±0.025 in SHRs expressing DREADD-Gs vs.  0.073±0.03 in SHRs 
expressing eGFP, p = 0.035 and 0.13±0.01 in Wistars expressing DREADD-Gs vs. 0.08±0.02 
in Wistars expressing eGFP, p = 0.038) (Figs. 3A-B). 
 
2.3) Heart rate and systolic arterial pressure and variability 
 The results of SAP and HR (PI) variability in the time and frequency domains from 
Wistar (controls: DREADD-Gs or eGFP) and SHRs (DREADD-Gs or eGFP) are showed in 
Figs. 3C-D and 4A-D. SAP variance and SAP LF were found to be lower in SHRs expressing 
DREADD-Gs as compared to SHRs expressing eGFP (p = 0.043) (Figs. 3C-D). The analysis 
of systolic AP variability showed no differences in PI variance. However, the SHRs 
expressing DREADD-Gs exhibited lower total power LF, and HF compared with SHR 
expressing e-GFP (p = 0.034) (Figs. 4B-C). Moreover, sympathovagal balance assessed by 
the LF/HF ratio, was shown to be lower in SHRs expressing DREADD-Gs compared to 
SHRs expressing eGFP (p = 0.032, Fig. 4D), suggesting a dominance of parasympathetic 
influences.  
Discussion 
 In this study, we have shown that using a pharmacogenetic approach for repetitive 
stimulation of DVMN neurons for 21 days produced significant cardiovascular benefits in 
SHRs, including decreased arterial blood pressure and improved spontaneous baroreflex 
sensitivity. These data are consistent with previous studies showing improved cardiac and 
vascular function by either direct [electrical vagal stimulation, acetylcholine (Ach) 
administration and ACh receptor activation] or indirect vagal modulation (adenosine, 
cholinesterase inhibitors, statins and exercise training) (see 16 for review). In recent years, 
vagal modulation techniques such as baroreflex activation therapy and direct vagal nerve 
stimulation have been proposed as adjuvant therapies for the treatment of arterial 
hypertension (35). However, to our best knowledge this is the first study where a well-
defined population of vagal preganglionic neurons has been selectively targeted for repetitive 
activation of central parasympathetic pathways in an animal model of arterial hypertension. 
Our results showed that arterial blood pressure was significantly reduced in SHRs 
transduced to express DREADD-Gs in the DVMN compared to SHRs expressing control 
eGFP, whilst Wistar rats showed no changes in cardiovascular parameters. This suggests that 
DVMN efferents might play an important role in the control of arterial blood pressure, 
however, the mechanisms are unclear. Ach is a powerful vasorelaxant that decreases blood 
vessel resistance by inducing phosphorylation of the rate-limiting enzyme involved in the 
biosynthesis of nitric oxide (NO), endothelial nitric oxide synthase (eNOS). Endothelium-
derived NO-induced synthesis decreases the availability of intracellular calcium, resulting in 
a decrease in myosin phosphorylation and vasorelaxation that would ultimately lead to 
decreased arterial blood pressure. However, the arterioles in skeletal muscle that determine 
peripheral resistance are paradoxically devoid of cholinergic innervation and therefore, 
changes in afterload are highly unlikely to be produced by direct stimulation of  
parasympathetic efferent pathways from the DVMN. Thus, the arterial blood pressure-
lowering effect of DVMN stimulation might be exerted elsewhere, probably at the level of 
the heart. Recent studies have shown that DVMN neurons provide a tonic inhibitory 
muscarinic influence on left ventricular contractility. Pharmacological activation of cardiac 
preganglionic vagal neurons that reside in the left caudal DVMN in the rat trigger profound 
reductions in left ventricular dp/dtmax (19). This suggests that reductions in arterial blood 
pressure in rats expressing DREADDS-Gs in the DVMN may have been the consequence of 
changes in cardiac output at the expense of reduced stroke volume and left ventricular 
inotropy. Long-term measurements of cardiac inotropy is needed to validate these claims. 
Stimulation of DVMN neurons was also associated with significant increases in 
baroreflex gain and effectiveness, both in SHRs as well as in Wistar rats. This suggests that 
DVMN stimulation might have improved baroreflex function, perhaps by inducing protective 
effects in baroreceptor function at the level of the great vessels. In recent years, several 
reports indicate that mechanical insults that increase arterial stiffening contribute directly to 
the development of arterial hypertension. Arterial stiffness is caused by disruption of elastin 
integrity in the aortic wall in particular with ageing, diabetes and chronic kidney disease. 
Stiffening at the level of the aortic root, impairs the Windkessel mechanism at this important 
interface, thereby reducing wave reflection and leading to increased central pulsatile pressure 
and transmission of excessive pulsatile energy that is known to promote end-organ damage. 
More importantly, reduced arterial compliance at higher pressures are believed to hamper 
baroreceptor activation thus causing a dysfunction in baroreflex control of heart rate and 
peripheral resistance. Studies performed in mouse models of impaired elastin expression have 
shown that stiffening of the aorta precedes the development of hypertension and subsequent 
increments in systolic pressure were inversely proportional to elastin content in the aorta (36). 
Interestingly, bilateral vagotomy in rats has been shown to induce similar structural 
remodeling changes leading to increased stiffening of the aorta (37). Even though arterial 
blood pressure was not reported in this study, this evidence suggests that the vagus nerve may 
prevent age-related structural changes in the great vessels that may contribute to the 
development of arterial hypertension. Future studies should endeavour to investigate whether 
long-term stimulation of DVMN efferent pathways induce protective metabolic and structural 
mechanisms that help to preserve and/or restore arterial wall compliance and thus facilitate 
arterial baroreceptor signaling. 
Our findings further suggest that the development of hypertension might be associated 
with impaired DVMN functionality in the SHR and conversely, increasing neuronal activity 
by pharmacogenetic methods might have helped to attenuate disease progression. 
Histological analysis of ChAT immunofluorescence revealed that SHRs and Wistar rats have 
similar neuronal numbers in the DVMN. However, the number of DVMN neurons 
retrogradely labeled from the heart was previously found to be significantly reduced in adult 
SHRs compared to young SHRs and adult Wistar Kyoto rats (38). This discrepancy suggests 
that the number of cardiovagal neurons that project to the heart is probably too small as to 
make a significant contribution to the overall population of vagal neurons residing in the 
DVMN and thus, a loss of cardiovagal neurons in adult SHRs may not have a major impact 
on the total number of DVMN neurons. However, age-related reduction in the population of 
DVMN neurons in the SHRs might also be accompanied with abnormalities in DVMN 
neuronal excitability. Previous studies have shown that parasympathetic neuronal dysfunction 
is a common feature in animal models of cardiovascular disease such as heart failure and 
chronic intermittent hypoxia in which increased GABAergic/glycinergic neurotransmission 
and decreased excitatory neurotransmission in the DVMN and nucleus ambiguous result in 
reduced neuronal excitability and lower parasympathetic tone (39, 40). Similar mechanisms 
are likely to operate in the SHR and should be further investigated in future studies to help 
determine whether DVMN synaptic dysfunction, a selective loss of parasympathetic 
preganglionic neurons supplying the heart or a remodelling of their cardiac projections, might 
promote abnormal changes in left ventricular inotropy and/or loss of structural integrity in the 
aortic wall which might contribute to the development of arterial hypertension.  
Our data showed that long-term activation of vagal preganglionic neurons within the 
DVMN resulted in a reduction in heart rate and systolic blood pressure variance exclusively 
in SHRs. This bradycardic effect in SHRs might have been caused by indirect reductions in 
sympathetic nerve trafficking in SHRs rather than by increased vagal influence on cardiac 
chronotopy since cardiac vagal preganglionic neurons that control the activity of the sino-
atrial node are generally believed to be located in the ventrolateral aspect of the nucleus 
ambiguous (NA) (41, 42) whilst DVMN neurons that were targeted in this study have 
virtually no influence on the control of heart rate (43). This is supported by PI variability 
analysis, showing significant reductions in the LF component, consistent with decreased 
sympathetic tone. Thus, a reduced heart rate in SHRs might have further contributed to lower 
cardiac output and produce concomitant reductions in arterial blood pressure in the SHRs 
expressing DREADD-Gs. This effect was only evident in SHRs and not in Wistar rats 
because SHRs have augmented sympathetic activity and would therefore be more sensitive to 
decreased sympathetic activity. Reference from Jim? 
Our results are consistent with recent studies showing that pharmacological activation 
of parasympathetic signaling elicits beneficial effects in the circulatory system. Transdermal 
application of scopolamine has been shown to decrease arterial blood pressure, increase 
baroreflex sensitivity and accentuate vagal-cardiac modulation of sinus node in patients with 
mild hypertension (44), supporting the hypothesis that increasing cardiovascular 
parasympathetic activity might have beneficial effects in subjects with arterial hypertension. 
More recently, systemic administration of choline was shown to restore the impaired cardiac 
function in SHRs, as evidenced by decreases in heart rate, systolic blood pressure, left 
ventricular systolic pressure, dp/dtmax and increases in ejection fraction and fractional 
shortening (45). This effect was accompanied by restored baroreflex sensitivity in SHRs and 
profound anti-inflammatory effects, including downregulation of interleukin (IL)-6 and 
tumour necrosis factor-α (TNF-α) and increased expression of IL-10 in the mesenteric 
arteries of SHRs, thus indicating that choline improved vagal activity (45). Similarly, chronic 
increase of acetylcholine availability induced by administration of anti-acetylcholinesterase 
agents with central and/or peripheral action, attenuated the development of hypertension, 
increased cardiac vagal tone, improved arterial pressure and pulse interval variability and 
reduced plasma levels of TNF-α, IL- 6, and interferon γ (46). Together, these 
pharmacological studies suggest that acetylcholine might attenuate the harmful 
cardiovascular effects of systemic low-grade inflammation, including endothelial 
dysfunction, oxidative stress and autonomic dysfunction. However, the effect of DVMN 
neuronal activation on the expression of pro-inflammatory mediators and signalling 
mechanisms requires further investigation. Control of low-grade signalling inflammation by 
stimulation of DVMN circuits may have a significant impact on the control of autonomic 
balance and cardiovascular homeostasis and ultimately contribute to the reduction in arterial 
blood pressure levels in the SHR. 
Our study has some limitations. We employed adult SHRs with fully-established 
arterial hypertension and 21 days of DVMN stimulation with CNO was relatively short. 
Thus, it remains to be determined whether these effects are similar or perhaps more effective 
when animals receive the treatment at different stages (i.e., prehypertensive stage or further 
down in the presence of end-organ damage) and whether arterial blood pressure-lowering 
effects can be sustained for considerably longer periods (months to years).  From a technical 
point of view, one of the major technical limitations was that blood pressure measurements 
were only acquired until the end of the study and for relatively short periods of time 
(normally 1 hour). Thus, longer data acquisitions were not possible, especially at night, so we 
were not able to assess the time course of the blood pressure-lowering effects of DVMN 
activation and whether blood pressure dipping was restored in SHRs. Finally, we did not 
determine whether the amount of lentiviral particles delivered achieved a maximum infection 
rate which could have affected the magnitude of the arterial blood pressure-lowering effect 
we obtained. However, despite these limitations, our study provides unequivocal evidence 
that shows that activation of DVMN neurons for 3 weeks is enough to substantially lower 
arterial blood pressure levels in adult SHRs and improve autonomic dysfunction. 
In conclusion, using a chemogenetic approach for highly selective recruitment of 
vagal efferent projections in the DVMN, we demonstrate that long-term activation of central 
parasympathetic pathways exerts arterial blood pressure-lowering effects in SHRs. Our data 
suggest that cardiac preganglionic neurones in the DVMN are important targets for increasing 
parasympathetic activity to the heart, and may provide a therapeutic strategy to help  control 
arterial hypertension and prevent its detrimental effects. 
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Figure legends 
Figure 1: Targeting cardiac preganglionic neurons in the dorsal motor nucleus of the 
vagus nerve (DVMN).  
A) Representative image of choline acetyl transferase (ChAT)-immunoreactive neurons (red) 
in the DVMN. B) DVMN neurons expressing DREADD-Gs-eGFP. C) merge of A and B in 
the intermediate aspect of the DVMN (13.8 mm caudal from Bregma). Most of the neurons in 
this image are double-labelled and appear orange. D) average number of counted neurons per 
section from 7 rats. Counts were made from a 1 in 6 series of 40 μm coronal sections. 
Abbreviations: AP, Area Postrema; cc, central canal; XII, hypoglossal motor nucleus. Scale 
bar in C = 500 m. 
 
Figure 2: Long-term activation of DREADD-Gs-expressing neurons in the dorsal motor 
nucleus of the vagus attenuates the hypertension in the spontaneously hypertensive rat 
(SHR).  
Summary data showing that long-term activation of DVMN neurons expressing DREADD-
Gs within the DVMN results in a significant reduction of resting A) mean (MAP), B) systolic 
(SAP), C) diastolic arterial blood pressure (DAP) and D) heart rate (HR) in the SHR. Note 
that activation of DREADD-Gs-expressing neurons in the DVMN did not affect 
physiological variables in Wistar rats. Data are presented as mean±SEM. *p<0.05 or 
***p<0.001, significant difference between SHRs expressing EGFP and SHRs expressing 
DREADD-Gs in the DVMN. N = 4-8/group of rats 
 
Figure 3: Power spectral analysis of the systolic arterial pressure (SAP) and 
spontaneous baroreflex sensitivity (SBR) after long-term activation of DREADD-Gs-
expressing neurons in the dorsal motor nucleus of the vagus in SHR and Wistar rats. 
Summary data showing that long-term activation of DVMN neurons expressing DREADD-
Gs within the DVMN results in significant changes in A) baroreflex gain (ms/mmHg); B) 
baroreflex effectiveness index; C) systolic arterial pressure (SAP) variance; D) Low 
frequency (LF) component of the SAP (mmHg2). Data are presented as mean±SEM. *p<0.05, 
significant difference between SHRs or Wistar rats expressing eGFP and SHRs and Wistar 
rats expressing DREADD-Gs in the DVMN. N = 4-8/group of rats 
  
Figure 4: Power spectral analysis of the pulse interval (PI) variability and spontaneous 
baroreflex sensitivity (SBR) after long-term activation of DREADD-Gs-expressing 
neurons in the dorsal motor nucleus of the vagus in SHR and Wistar rats. 
Summary data showing that long-term activation of DVMN neurons expressing DREADD-
Gs within the DVMN results in significant changes in A) Pulse interval (PI) variability; B) 
LF component of PI (%); C) High frequency (HF) component of PI (%) and D) LF/HF ratio 
in SHR and Wistar rats. Data are presented as mean±SEM. *p<0.05, significant difference 
between SHRs or Wistar rats expressing EGFP and SHRs and Wistar rats expressing 
DREADD-Gs in the DVMN. N = 4-8/group of rats 
 
 
 
 
 
 
  
 
